Extracellular cysteine/cystine redox regulates the p44/p42 MAPK pathway by metalloproteinase-dependent epidermal growth factor receptor signaling.
Previous research shows that stimulation of proliferation of colon carcinoma (Caco-2) cells by a more reduced extracellular cysteine/cystine (Cys/CySS) redox state occurs with no apparent effect on intracellular glutathione and that this stimulation is lost on addition of epidermal growth factor. The purpose of the present study was to determine whether a more reduced extracellular Cys/CySS redox state activates the mitogenic p44/p42 mitogen-activated protein kinase (MAPK) pathway and whether this is signaled through the epidermal growth factor receptor (EGFR). Caco-2 cells were exposed to a range of physiological extracellular redox conditions from -150 to 0 mV. In the absence of added growth factors, the most reduced (-150 mV) redox state induced an 80% increase in EGFR phosphorylation, and this was followed by a marked increase in phosphorylation of p44/p42 MAPK. Inhibitors of EGFR (AG1478) and p44/p42 MAPK (U0126) phosphorylation blocked redox-dependent p44/p42 phosphorylation, indicating that signaling occurred by EGFR. These effects were inhibited by pretreatment with a nonpermeant alkylating agent, showing that signaling involved thiols accessible to the extracellular space. The EGFR ligand TGF-alpha was increased in culture medium at more reduced redox states. Redox-dependent phosphorylation of EGFR was completely prevented by a metalloproteinase inhibitor (GM6001), and an antibody to TGF-alpha partially inhibited the phosphorylation of p44/p42 MAPK by redox. Thus the data show that a redox-dependent activation of metalloproteinase can stimulate the mitogenic p44/p42 MAPK pathway by a TGF-alpha-dependent mechanism. Because Cys availability and Cys/CySS redox are dependent on nutrition, disease, and environmental exposures, the results suggest that cell proliferation could be influenced physiologically by Cys-dependent redox effects on growth factor signaling pathways.
Nkabyo
Yvonne S
YS
Graduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia 30322, USA.
Go
Young-Mi
YM
Ziegler
Thomas R
TR
Jones
Dean P
DP
D000963:Antimetabolites / Q000493:pharmacokinetics; D001973:Bromodeoxyuridine / Q000493:pharmacokinetics; D018938:Caco-2 Cells; D003545:Cysteine / Q000378:metabolism*; D003553:Cystine / Q000378:metabolism*; D004220:Disulfides / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005110:Extracellular Space / Q000201:enzymology; D006801:Humans; D007422:Intestines / Q000166:cytology / Q000201:enzymology*; D020935:MAP Kinase Signaling System / Q000502:physiology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D010084:Oxidation-Reduction; D010766:Phosphorylation; D013438:Sulfhydryl Compounds / Q000378:metabolism; D016211:Transforming Growth Factor alpha / Q000378:metabolism
D000963:Antimetabolites; D004220:Disulfides; D013438:Sulfhydryl Compounds; D016211:Transforming Growth Factor alpha; D003553:Cystine; D066246:ErbB Receptors; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D001973:Bromodeoxyuridine; D003545:Cysteine